Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised …

T Nordström, A Discacciati, M Bergman… - The Lancet …, 2021 - thelancet.com
Background Screening for prostate cancer using prostate-specific antigen (PSA) reduces
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …
被引用次数：122 相关文章

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised …

T Nordström, A Discacciati, M Bergman… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Screening for prostate cancer using prostate-specific antigen (PSA) reduces
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised …

T Nordström, A Discacciati, M Bergman… - The Lancet …, 2021 - europepmc.org
Background Screening for prostate cancer using prostate-specific antigen (PSA) reduces
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised …

T Nordström, A Discacciati, M Bergman, M Clements… - The Lancet …, 2021 - Elsevier
Background Screening for prostate cancer using prostate-specific antigen (PSA) reduces
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised …

T Nordström, A Discacciati, M Bergman, M Clements… - 2021 - cabidigitallibrary.org
Background: Screening for prostate cancer using prostate-specific antigen (PSA) reduces
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised …

T Nordström, A Discacciati, M Bergman… - The Lancet …, 2021 - elibrary.ru
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate
biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority …

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised …

T Nordström, A Discacciati, M Bergman… - The Lancet …, 2021 - thelancet.com
Background Screening for prostate cancer using prostate-specific antigen (PSA) reduces
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …